1. CLINICO-ECONOMICAL IMPACT OF HTA IMPLEMENTATION ON CHEST PAIN DIAGNOSTIC MARKERS Dott. FilippoBartoccioni U.O. Clinical Governance S. Camillo – Forlanini Hospital

2. WHY AN HTA ON CHEST PAIN DIAGNOSTIC MARKERS PRESCRIPTION? TECHNOLOGY IMPROVEMENT GUIDELINE MODIFICATION MAIN DIAGNOSTIC MARKERS OF CHEST PAIN: TROPONIN I and T CK-MB MYOGLOBIN

3. METHODOLOGY OF TECHNOLOGY STUDY Technologies Yes, Itshouldbeused No Indication X3= note Clinical presentations

4. INTERVENTION OUTCOME GRAPHICS

5. CLINICAL IMPACT VERIFICATION THROUGH STATISTICAL ANALYSIS CONFIDENCE INTERVAL CONTAINS NUMBER ONE NULL HYPOTESIS IS CONFIRMED THERE IS NOT ANY DIFFERENCE BETWEEN BEFORE AND AFTER THE INTERVENTION

6. ECONOMICAL ANALYSIS

7. S. Camillo- Forlanini U.O. Formazione e Governo Clinico APPROPRIATENESS AND ECONOMICAL IMPACT We started from an average of about 1100 myoglobin / month / PS’ s tests.The intervention led to a required’s reduction amounts to 96.78%.

8. Thank you for your attention Contacts: nucleohta@gmail.com NucleoHTA